Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWIFT: Brolucizumab for Suboptimal nAMD
NCT04264819Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2020
- Primary completion
- Oct 2022
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Primary endpoint: Number of Patients With no Disease Activity at Week 16 in the Study Eye. Started Dec 2020; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04264819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264819.